To define the role of rare variants in advanced age-related macular degeneration (AMD) risk, we sequenced the exons of 681 genes within all reported AMD loci and related pathways in 2,493 cases and controls. We first tested each gene for increased or decreased burden of rare variants in cases compared to controls. We found that 7.8% of AMD cases compared to 2.3% of controls are carriers of rare missense CFI variants (odds ratio (OR) = 3.6; P = 2 × 10 −8 ). There was a predominance of dysfunctional variants in cases compared to controls. We then tested individual variants for association with disease. We observed significant association with rare missense alleles in genes other than CFI. Genotyping in 5,115 independent samples confirmed associations with AMD of an allele in C3 encoding p.Lys155Gln (replication P = 3.5 × 10 −5 , OR = 2.8; joint P = 5.2 × 10 −9 , OR = 3.8) and an allele in C9 encoding p.Pro167Ser (replication P = 2.4 × 10 −5 , OR = 2.2; joint P = 6.5 × 10 −7 , OR = 2.2). Finally, we show that the allele of C3 encoding Gln155 results in resistance to proteolytic inactivation by CFH and CFI. These results implicate loss of C3 protein regulation and excessive alternative complement activation in AMD pathogenesis, thus informing both the direction of effect and mechanistic underpinnings of this disorder.
l e t t e r s
To define the role of rare variants in advanced age-related macular degeneration (AMD) risk, we sequenced the exons of 681 genes within all reported AMD loci and related pathways in 2,493 cases and controls. We first tested each gene for increased or decreased burden of rare variants in cases compared to controls. We found that 7.8% of AMD cases compared to 2.3% of controls are carriers of rare missense CFI variants (odds ratio (OR) = 3.6; P = 2 × 10 −8 ). There was a predominance of dysfunctional variants in cases compared to controls. We then tested individual variants for association with disease. We observed significant association with rare missense alleles in genes other than CFI. Genotyping in 5,115 independent samples confirmed associations with AMD of an allele in C3 encoding p.Lys155Gln (replication P = 3.5 × 10 −5 , OR = 2.8; joint P = 5.2 × 10 −9 , OR = 3.8) and an allele in C9 encoding p.Pro167Ser (replication P = 2.4 × 10 −5 , OR = 2.2; joint P = 6.5 × 10 −7 , OR = 2.2). Finally, we show that the allele of C3 encoding Gln155 results in resistance to proteolytic inactivation by CFH and CFI. These results implicate loss of C3 protein regulation and excessive alternative complement activation in AMD pathogenesis, thus informing both the direction of effect and mechanistic underpinnings of this disorder.
AMD leads to irreversible vision loss in individuals over 55 years of age [1] [2] [3] . Most known genetic AMD variants are common, without established disease mechanisms 4 . So far, highly penetrant missense variants for AMD are only known in CFH 5 . We sought to identify additional rare missense risk variants with the goal of identifying specific disease mechanisms.
We applied targeted next-generation sequencing to coding regions of candidate genes within AMD-associated loci and pathways (Online Methods and Supplementary Fig. 1 ). Informed consent was obtained from each subject, and the institutional review board at each clinical site approved the study. To maximize power, we prioritized cases with severe disease, familial disease or early age of onset, as well as older controls without drusen. We sequenced 681 genes to >20× coverage for a median of 95.6% of the targeted region ( Supplementary Fig. 2 ). After calling variants with the Genome Analysis Toolkit (GATK) 6 and applying strict quality control, we obtained genotype data for 1,676 cases, 745 controls and 36 siblings with discordant disease status (n = 2,493). Our data had <0.92% missing genotypes for each allele and <0.54% missing genotypes for each individual. We observed effect sizes comparable to published values for known AMD risk variants or proxies (Supplementary Table 1 ). Many variants discovered in our sequencing study were not genotyped or imputed in recent AMD genome-wide association studies (GWAS) (Supplementary Fig. 3) .
We compared sequencing-based genotypes to genotypes from the HumanExome BeadChip array (exome chip) 7, 8 . We observed 99.97% concordance for 2,426 missense SNPs that were captured by both sequencing and exome chip with allele frequencies (f ) ≥0.001 (Online Methods). Allelic dosages were almost perfectly correlated (r > 0.99) for 96.5% of common variants (f > 0.01) and 93.0% of rare variants ( Supplementary Fig. 4) ; only 0.2% and 3.6% of common and rare SNPs, respectively, had modestly correlated dosages (r < 0.9).
With the sequencing data, we tested whether any of 681 genes had a higher burden of rare variants in cases or in controls. We selected only rare variants (f < 0.01) within targeted genes that altered coding sequences (missense, nonsense, read-through or splice variants; n = 15,762 SNPs). We used a simple burden test to assess whether the proportion of case individuals who carried at least one rare variant was in excess of the proportion expected by chance (Online Methods and Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration l e t t e r s Supplementary Table 2a ) 9 . We similarly tested increased burden in controls. To interpret statistical significance, we applied a Bonferronicorrected significance threshold of P < 3.6 × 10 −5 (0.05/(681 genes × 2 tests)). We saw a significantly increased burden in cases in only one gene, CFI (exact one-tailed P = 1.6 × 10 −8 ; OR = 3.57 ; Fig. 1a) ; 7.8% of cases had a rare coding variant compared to 2.3% of controls. In contrast, using the C-alpha test 10 , we found no evidence of any genes with alleles acting in opposite directions (Supplementary Table 2a ).
The enrichment of rare coding variants in CFI is likely not due to confounding by population stratification, sequencing artifact, age or sex. First, if the enrichment was due to stratification, then other genes would also demonstrate enrichment for rare variants; however, burden tests for other genes did not exceed expectation due to chance (Fig. 1a) . Second, stratification would also drive enrichment of synonymous variants; however, we observed no significant case enrichment for rare synonymous variants in CFI (P = 0.89) or in any of the 681 genes (P > 0.001; Supplementary Tables 2a and 3) . Third, to adjust for case-control stratification, we calculated principal components on the basis of ancestryinformative markers in a subset of 1,558 cases and 683 controls with exome-chip genome-wide genotyping data. We found that carriers of rare variants in CFI did not cluster along the top two principal components (Supplementary Fig. 5 ). Furthermore, adjusting for the top five principal components in a logistic regression framework caused no change in the case enrichment of rare CFI coding variants (P = 5.0 × 10 −8 , OR = 3.6 versus P = 1.1 × 10 −7 , OR = 3.5 after adjustment). To rule out effects from sequencing artifacts, we confirmed 137 of the 140 rare variant events assayed with Sanger sequencing (Online Methods and Supplementary  Fig. 6 ). The observed enrichment remained significant after adjusting for age and sex (P = 6.7 × 10 −9 , OR = 3.7 versus P = 1.1 × 10 −8 , OR = 3.6 after adjustment). We note that, because extreme phenotypic samples were prioritized for sequencing, independent replication in prospectively ascertained samples will ultimately be necessary to accurately estimate relative enrichment of rare CFI variants within the general population.
The enrichment in cases of rare coding variants in CFI was independent of the nearby common risk allele rs4698775 (refs. 4,11) . When we stratified our samples for rs4698775 genotypes, we observed consistent enrichment of rare coding variants in CFI across all three rs4698775 genotypes (P = 1.7 × 10 −8 ; Fig. 1b) . Moreover, the risk conferred by the common rs4698775 allele was independent of carrier status for rare variants (P < 0.04; allelic OR = 1.15), arguing against a 'synthetic association' .
We then used PolyPhen-2 (ref. 12) to classify the 59 separate CFI nucleotide variants into 4 categories on the basis of their potential predicted impact: (i) loss of function (nonsense or splice variants) 13 , (ii) probably damaging, (iii) possibly damaging and (iv) benign ( Fig. 2a and Supplementary Table 4) . The distribution of variants predicted to result in loss of protein function (three nonsense variants and one splice variant) was the most skewed, and these variants were exclusively found in cases (seven cases compared to zero controls; Fig. 2b ). The distribution of probably damaging variants was more skewed toward cases (41 cases compared to 3 controls) than possibly damaging variants (16 cases compared to 3 controls) and benign variants (70 cases compared to 12 controls). Indeed, probably damaging or lossof-function variants conferred high risk of disease (P = 1.3 × 10 −5 ; OR = 7.5). Further, some of the variants classified as benign are potentially pathogenic and are inaccurately classified by PolyPhen-2 (ref. 14) .
CFI encodes complement factor I, which consists of a heavy chain and a light chain, with a catalytic serine protease domain that cleaves the C3 protein. There was a greater burden of rare variants that affected the catalytic light chain (P = 2.2 × 10 −6 ; OR = 4.85) than affected the heavy chain (P = 0.0012; OR = 2.63). We observed no statistically significant evidence of association with AMD for any of the individual CFI variants (P > 0.02), possibly owing to their low frequency.
Notably, many of these rare variants in CFI have been found in individuals with atypical hemolytic uremic syndrome (aHUS), including ones encoding p.Pro50Ala 15 21 , whereas p.Pro50Ala, p.Ile416Leu and p.Arg474* produce a quantitative deficiency in CFI protein 15 . Despite extensive study, no functional deficiency for the p.Gly261Asp variant has been identified 17 .
We also tested rare variants individually for association with AMD ( Supplementary Fig. 1 ). This study was not powered to detect association for variants observed fewer than five times; thus, we excluded extremely rare SNPs from this analysis. We tested 1,824 variants within the 681 sequenced genes that had an allele frequency of <1% in cases or controls (Online Methods and Supplementary Table 2b). To interpret statistical significance, we applied a Bonferroni-corrected significance threshold of P < 1.4 × 10 −5 (0.05/(1,824 variants × 2 tests)).
We identified 5 risk and 15 protective variants that demonstrated nominal evidence of association in the discovery phase (exact onetailed P < 0.01; Supplementary Table 5) . Four of these variants were within or near CFH, including the previously reported CFH risk variant encoding p.Arg1210Cys (P = 0.0012) 5 . In addition, we observed association with the CFH variant encoding p.Asn1050Tyr, the CFHR2 variant encoding p.Tyr264Cys and the CFHR5 variant encoding p.Gly278Ser, which are protective. After phasing common variants within the CFH locus, we observed that the rare associated variants were in linkage disequilibrium (LD) with CFH haplotypes (Supplementary Fig. 7 ). We were uncertain whether these associations We tested 681 sequenced genes for increased burden of rare (f < 0.01) missense, nonsense, splice or read-through variants. Here we plot the observed P value for each gene as a function of the expected P value. We tested enrichment for carriers of rare variants in cases (red) and controls (yellow) separately. We indicate the threshold of significance after multiple-hypothesis testing (dashed red line, P < 3.6 × 10 −5 = 0.05/(681 genes × 2 tests)). We observed significant enrichment of rare variants in cases in only one gene, CFI. (b) We stratified individuals by their genotype at rs4698775, an associated common variant near CFI; the G minor allele has previously been reported to be associated with risk. We observed that rare variants are enriched on all genotypic backgrounds in cases compared to controls. npg 1 3 6 8 VOLUME 45 | NUMBER 11 | NOVEMBER 2013 Nature GeNetics l e t t e r s represented unique effects or were tagging CFH haplotypes with large effects, driven by the common risk allele at rs10737680 and by the common allele encoding p.Tyr402His [22] [23] [24] .
We evaluated 11 of the 16 variants outside of the CFH locus in an independent set of 2,227 cases and 2,888 controls from Boston, Baltimore and France genotyped by exome chip or TaqMan assays   Signal  peptide  FIMAC  SRCR  LDLR1  LDLR2   Heavy chain  Light chain   40  80  120  160  200  240  280  320  360  400  440  480  520  560 CFI Peptidase S1 Each row represents association statistics for the sample collections. The first row (Boston) represents our discovery data set and lists genotype counts in the case-control samples and in 49 discordant sibling pairs with exact one-tailed association P values. We list one-tailed P values with and without conditioning for the common variant rs2230199 in C3 encoding p.Arg102Gly. Other rows list similar statistics for each of the replication cohorts. The last row represents the joint analysis of all samples. Because we initially tested a total of 1,824 variants for risk and for protection, the multiple-hypothesis-corrected significance threshold for joint analysis is P < 1.4 × 10 −5 .
l e t t e r s (Supplementary Table 6 ). To increase power, we incorporated shared controls in this replication study (Online Methods); these controls may result in decreased allelic effect sizes because some may ultimately develop advanced AMD. We observed independent evidence of association for two variants in replication (P < 0.0031 = 0.05/16) and joint (P < 1.4 × 10 −5 ) analysis: the rs147859257 (p.Lys155Gln) variant in C3 (exact one-tailed P = 4.8 × 10 −6 in the discovery phase) and the rs34882957 (p.Pro167Ser) variant in C9 (exact one-tailed P = 2.3 × 10 −3 in the discovery phase; Tables 1 and 2 and Supplementary  Table 5 ). Both variants had perfectly concordant sequencing-based and exome-chip genotypes (r = 1). To assess whether either association could be related to population stratification, we calculated principal components for a subset of samples (n = 2,241) as described above. Individuals who were carriers of either variant did not cluster along the first two principal components ( Supplementary  Figs. 8 and 9) . Also, adjusting for the top five principal components caused no change in the effect mediated by the p.Lys155Gln variant (P = 2.7 × 10 −5 , OR = 16.1 versus P = 2.0 × 10 −6 , OR = 16.7 after adjustment) or in the effect mediated by the p.Pro167Ser variant (P = 0.053, OR = 2.0 versus P = 0.053, OR = 2.0 after adjustment). These associations retained significance after adjusting for age and sex (P = 1.5 × 10 −5 , OR = 9.5 versus P = 1.5 × 10 −5 , OR = 9.0 for p.Lys155Gln after adjustment; P = 0.007, OR = 2.3 versus P = 0.01, OR = 2.2 for p.Pro167Ser after adjustment). The C3 variant encoding p.Lys155Gln (position 133 excluding the signal peptide) demonstrated compelling evidence of association in replication analysis (P = 3.5 × 10 −5 ; OR = 2.8) and was highly significantly associated with a large effect size in joint analysis with discovery samples (P = 5.2 × 10 −9 ; OR = 3.8; Table 1 ). Whereas the estimated effects for p.Lys155Gln in the discovery and replication phases had overlapping confidence intervals, the effect in the discovery phase was larger, perhaps related to 'winner's curse' (ref. 25) or inclusion of shared controls in the replication phase. This risk was independent from that explained by a previously reported common risk variant, p.Arg102Gly (rs2230199) 26, 27 . In a subset of samples with genotypes for p.Arg102Gly and p.Lys155Gln (n = 6,935, excluding Baltimore samples), we observed increased significance of the effect mediated by p.Lys155Gln when we stratified individuals on the basis of their genotypes for p.Arg102Gly (from P = 5.4 × 10 −9 to 6.2 × 10 −10 ; Table 1 ). The risk variant encoding p.Lys155Gln was in phase with the protective allele rs2230199[G] encoding Arg102. The C9 variant encoding p.Pro167Ser also demonstrated convincing association in replication analysis (P = 2.4 × 10 −5 ; OR = 2.2) and in joint analysis (P = 6.5 × 10 −7 ; OR = 2.2; Table 2 ). Whereas the p.Pro167Ser variant is predicted with high confidence to be a probably damaging variant by PolyPhen-2 (ref. 12) , there were no reported functional data for this variant. We note that one other independent nominal association has previously been reported in C9 (ref. 28) . Our study expands the repertoire of AMD-associated genes in the complement cascade, specifically implicating the membrane attack complex (C5-C9) that is formed downstream of C3 activation in the activation of the alternative complement pathway.
We note that p.Lys155Gln is on the surface of C3, close to the binding site for CFH (Supplementary Fig. 10 ) 29 , which is a cofactor for CFI-mediated cleavage of C3. We therefore tested the hypothesis that the p.Lys155Gln substitution in C3 might confer resistance to its inactivation by CFI, using a previously described experimental strategy for evaluating mutations in aHUS 30 . Notably, we observed significantly reduced cleavage of C3 with Gln155 compared to C3 with Lys155 in fluid-phase cofactor assays (Fig. 3a,b) . We also observed significantly reduced binding to CFH by the protein with Gln155 in surface plasmon resonance (~60%; P < 0.03; Supplementary Fig. 11a ) and a trend toward reduced binding with ELISA (Supplementary Fig. 11b ). In contrast, MCP cofactor activity was not reduced by the p.Lys155Gln substitution (Supplementary Fig. 12a-c) . We observe that the α chain is cleaved much less efficiency with Gln155 than with Lys155. In parallel, we see accumulation of the α 40 cleavage fragment in proportion to α-chain cleavage. The α 1 cleavage fragment is not visualized because it migrates at the same molecular weight as the β chain. (b) We quantified the reduction in the amount of the α chain by densitometry of four independent experiments; here we present the mean ± s.e.m. at each time point. We assessed significance with an unpaired t test: *P < 0.03.
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We conclude that the variant in C3 encoding p.Lys155Gln primarily impairs C3b regulation by CFI with bound CFH, resulting in increased C3 convertase formation and feedback amplification of the alternative complement pathway (Supplementary Fig. 13 ). This pattern of reduced regulatory activity mirrors that of the highly penetrant p.Arg1210Cys substitution in CFH, which also disrupts CFH binding to C3b [31] [32] [33] . The burden of CFI mutations, particularly of the loss-of-function mutations affecting the catalytic domain of the protein, along with the large effect of the p.Lys155Gln and p.Arg1210Cys variants underscores the critical role of impaired alternative pathway regulation by dysfunction of the C3b-CFH-CFI trimolecular interaction. These observations parallel mounting evidence that common AMD risk alleles might also lead to increased alternative pathway activity [34] [35] [36] . These results suggest the potential of agents that prevent C3 activation or enhance CFI or CFH activity to reduce the risk or progression of disease. Strikingly, our study did not identify rare variants outside the complement pathway, despite the large set of genes queried within other AMD-associated loci and genes involved in angiogenesis, lipid metabolism and extracellular matrix signaling 4, [37] [38] [39] . One possibility to explore, as sequencing studies scale up in size, is that rare coding variants with even more modest effect sizes than those reported here may modulate AMD risk within those other genes as well.
MeTHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ONLINe MeTHODS
Study sample descriptions. Case definitions.
Board-certified ophthalmologists evaluated all case subjects and matched (non-shared) control subjects. We either (i) clinically evaluated with visual acuity measurements, dilated slit-lamp biomicroscopy and stereoscopic color fundus photography or (ii) reviewed full ophthalmological medical records and images. Cases had either geographic atrophy (advanced dry AMD) or neovascular disease (wet AMD) according to Clinical Age-Related Maculopathy Grading System (CARMS) stages 4 and 5 (ref. 40) . Controls were also examined and had no signs of intermediate or advanced macular degeneration in either eye and absence of bilateral early AMD. All Boston and France controls and most Baltimore controls (>80%) were ≥60 years old.
Boston. Subjects were recruited through ongoing AMD study protocols 2,11,24,41-43 . After quality control, these samples ultimately included 2,422 unrelated cases and 1,287 unrelated controls, as well as 49 discordant sibling pairs. We applied targeted sequencing to a subset of these samples, including 1,676 unrelated cases and 745 unrelated controls, as well as in 36 siblings with discordant case status passing quality control. We applied the Illumina Infinium HumanExome genotyping array to an independent set of 746 cases, 542 controls and 13 siblings with discordant case status for replication passing stringent quality control. To assess concordance, we successfully genotyped a subset of 1,558 sequenced cases and 683 sequenced controls with the Illumina HumanExome genotyping array. Sequenced controls had a mean age of 77.2 years, whereas sequenced cases had a mean age of 75.6 years ( Supplementary Fig. 14) .
France. We recruited AMD cases and controls at the Hôpital Intercommunal de Creteil (FR-CRET; Creteil, France) as previously described 37,38 who were self-described white individuals of European descent. We genotyped all samples with the Illumina HumanExome genotyping array. These samples included 953 unrelated cases and 203 unrelated controls after quality control.
Baltimore. Unrelated subjects were recruited at Johns Hopkins Hospital (Baltimore, Maryland) as previously described 37,38,44,45 and were selfdescribed white individuals of European descent. After quality control, we obtained genotype data from 516 cases and 163 controls for selected SNPs with TaqMan assays.
Shared controls. We used a collection of shared control samples from four separate studies broadly consented for medical use and genotyped at the Broad Institute. In aggregate, these samples included 2,466 samples passing quality control from individuals who were not evaluated for retinal diseases who were of European descent and unrelated. Samples included control individuals recruited for the 1000 Genomes Project (n = 448) 46 , the International Serious Adverse Event Consortium (iSAEC; n = 709) 47 , National Institute of Mental Health controls (n = 1,054) 48 and the Prospective Registry in inflammatory bowel disease (IBD) Study at Massachusetts General Hospital (PRISM; n = 255) 49 . Ultimately, in the final analysis, we selectively added 1,491 of these shared controls to the Boston collection and 476 of these shared controls to the France collection.
Targeted sequencing. Gene selection. We first selected all genes within 19 genomic regions defined by common SNPs that have been associated with AMD and obtained genome-wide significance in a recent large meta-analysis 4 . Then, we selected genes closest to common SNPs with nominal significance (P < 1 × 10 −4 ) in a smaller previous meta-analysis 37 . Next, we selected genes involved in pathways implicated in AMD or other retinal diseases, including complement genes, angiogenesis genes, genes involved in the structure of the retinal pigment epithelium (RPE) and photoreceptors, high-density lipoprotein (HDL) metabolism genes, genes involved in inflammation and oxidation pathways and genes in the extracellular and collagen matrix pathways. Finally, we included genes reported to be associated with related diseases, including Stargardt disease, Best disease or vitelliform macular dystrophy, Alzheimer's disease and aHUS.
Target capture and resequencing. We sequenced samples at PerkinElmer, Inc. We designed a custom Agilent SureSelectXT kit to capture the genomic sequences of coding exons, splice junctions and 5′ UTR and 3′ UTR regions in 765 selected genes with indexing barcodes for each sample. We sequenced a total target length of 5.28 Mb including 1.76 Mb of coding exons. We isolated the hybridized library fragments, quantified by quantitative PCR (qPCR) and sequenced, and then sequenced paired-end reads with the Illumina HiSeq 2000 sequencing platform. We required sequencing data for each sample to have over 10× coverage at greater than 90% of targeted regions and over 20× coverage at greater than 80% of targeted regions.
Read mapping, variant detection and annotation. We aligned sequence reads in each individual to the human reference genome (NCBI Build 37.3, hg19) with Burrows-Wheeler Aligner (BWA, v0.59) 50 . We called the consensus genotypes in the target regions with GATK (v2.18) with the workflow and parameters recommended in best practice variant detection with GATK v4 (refs. 6,51) . We applied GATK duplicate removal, indel realignment and base quality score recalibration and performed multi-sample SNP and indel discovery and genotyping across all samples simultaneously using variant quality score recalibration (VQSR). Other than high-quality variants assigned 'PASS' by VQSR, we also included only those variants in lower tranches with truth sensitivity between 99.0 and 100 that were also separately recorded in the exome Sequencing Project (ESP) database of 6,500 samples 52 . We annotated variants with snpEff (v2.05) 53 .
Quality control. We further excluded SNPs failing the Hardy-Weinberg test in controls (P < 1 × 10 −6 ). We also excluded alleles from further analysis that had high missing genotype data (>1%), likely owing to systematic low coverage or difficulty mapping reads across many samples. We also excluded samples with high missing genotype data (>1%) for common alleles with >1% frequency in our data set. For burden testing, we only tested those genes on autosomes that obtained >10× coverage at an average of >90% of the targeted region and had rare coding variants (n = 681).
Validation Sanger sequencing.
We sequenced the CFI gene in individuals who were carriers of rare CFI variants at Beckman Coulter Genomics. We designed primers (Supplementary Table 7 ) to produce 400-to 600-bp amplicons that were at least 50 bp from the intron-exon boundary was included to assure highquality sequence for splice sites and the entire exon sequence. We sequenced by applying capillary electrophoresis using the ABI Prism 3730xl DNA Analyzer platform (Applied Biosystems) with forward and reverse PCR primers. We assembled chromatograms using CONSED and detected polymorphisms with polyphred 5.04 (University of Washington).
Array-based genotyping of coding variants. We genotyped the France and Boston sample sets with the Illumina Infinium HumanExome BeadChip (v1.0), which provides coverage of over 240,000 functional exonic variants selected from >12,000 whole-exome and whole-genome sequences. In addition, we customized our assay by adding 3,214 SNPs in candidate AMD genes. We conducted genotyping at the John Hopkins Genotyping Core Laboratory. We genotyped shared control samples separately at the Broad Institute using the Illumina HumanExome v1.0, v1.1 and v1.1+ custom-content SNP arrays.
We called genotypes using Illumina's GenomeStudio software and then zCall 7 . We required that samples have <2% missing genotype calls for common variants (MAF > 5%) before applying zCall. Then, after applying zCall, we removed duplicate SNPs, monomorphic SNPs, SNPs with a low call rate (<98%) and SNPs failing the Hardy-Weinberg test (P < 1 × 10 −6 ). We merged genotype calls from the four shared control cohorts and the AMD cohort by only including SNPs that passed quality control in all five cohorts and passed Hardy-Weinberg test (P > 1 × 10 −6 ) across all samples.
TaqMan genotyping of selected SNPs. We genotyped Baltimore samples at the Duke University Center for Human Disease Modeling using a custom-made TaqMan genotyping assay by Applied Biosystems with the ABI 7900 Real-Time PCR system (Supplementary Table 7 ).
Statistical analyses. Removing related samples. For sequenced samples, we assessed relatedness by calculating genome-wide proportion identityby-descent estimates (PIHAT values) using common (f > 5%) SNPs pruned to insure independence with the -indep option in PLINK with default parameters (VIF = 2; window size = 50 SNPs) 54 . We identified pairs of sequenced individuals with PIHAT > 0.2 who were not known discordant sibling pairs and removed one of each pair of individuals from the analysis. We similarly estimated PIHAT for all replication samples genotyped by exome chip. We removed any individual in replication with PIHAT > 0.2 to another individual npg or to sequenced discovery samples. We also identified pairs of individuals in replication samples with PIHAT > 0.2 that were not a known discordant sibling pair and removed one of these pairs from the analysis.
Assessing concordance of array-based and sequencing-based genotypes. Because rare SNPs are challenging to genotype with array-based platforms, we selected only those alleles with minor allele counts of ≥5 (allele frequency > 0.1%). We also selected only those SNPs with 0% missingness in the array data to ensure the highest possible accuracy for array-based genotypes. To assess concordance, we calculated simple concordance between genotype dosages across individuals with the two different platforms. This correlation-based metric is comparable across allele frequency spectrums.
Ancestry informative markers. For samples genotyped on the exome chip, we identified 16,008 ancestry-informative markers. To identify these SNPs, we selected SNPs on the exome chip with common allele frequencies (f > 5%) and excluded regions in the CFH locus (chr. 1: 195.5-197.5 Mb in hg19 coordinates), the ARMS2 locus (chr. 10: 123-125 Mb) and the major histocompatibility complex (MHC) locus (chr. 6: 25-35 Mb). We then pruned the resulting set of SNPs using the -indep option in PLINK with default parameters (VIF = 2; window size = 50 SNPs) 54 .
Combining shared controls. For samples genotyped by exome chip in the France and Boston data sets, we included shared controls to increase power. To mitigate the potential effects of population stratification in these replication data sets, we included shared controls in each collection by matching on case ancestry. First, we applied EIGENSTRAT to these SNP genotypes to calculate principal components to match samples in replication samples together with shared controls 55 . Then we used the first five principal components to calculate Euclidean distances between samples in the Boston and France cohorts and shared control samples. Finally, we randomly selected individual case samples in these cohorts and assigned the nearest unassigned shared controls to the selected case's cohort. Shared controls could only be assigned to one of two cohorts. We added about 1 shared control for every 2 cases to the France collection such that, in total, we added 476 shared controls. We also added about 2 shared controls for every 1 case to the Boston replication collection such that, in total, we added 1,491 shared controls. The resulting expanded Boston and France cohorts had minimal evidence of population stratification (λ GC = 1.04 and 1.06, respectively, for ancestry-informative markers).
Statistical framework for association testing. Because asymptotic statistics can be inaccurate for rare variants, we instead used exact statistics to test association for individual variants and also for sets of variants in genes (burden tests). We used a strategy similar to that described in Raychaudhuri et al. 5 .
For single-strata case-control sample collections, we used a 2 × 2 Fisher's exact test to calculate a one-tailed P value. Assuming that in a single strata that there are a total of N individuals, of whom n case are cases and n variant are carriers of the variant, we calculate the one-tailed significance of observing n variant,case individuals who had the variant and had advanced AMD as
where hg is the hypergeometric probability distribution assuming that there are n variant draws from a total of N samples, of which x of a total of n case are drawn.
If multiple case-control strata are present, for example, if we are stratifying genotypes of a common variant or combining multiple case-control collections together, we expand the above strategy to calculate an exact P value. Assuming that we observe a total of n variant,case carriers who are affected across all strata, then, we can calculate significance as follows: Here, for each strata j, we have separate numbers of total individuals (N j ) and separate numbers of individuals who are cases (n j,case ) and heterozygote individuals (n j,variant ). So, we calculate the hypergeometric probability for each individual strata for all the possible counts that would result in an equal or greater than n variant,case total number of heterozygotes associated with advanced AMD, and we total these probabilities together to obtain a P value. For discordant siblings, we calculated statistical significance using the binomial distribution. For a given variant, we considered only those pairs of siblings with discordant genotype for the rare variant. The probability under the null hypothesis that the affected sibling will have the variant is 0.5. We assigned each discordant sibling pair a score, s i , which is 1 if the affected sibling has the rare variant or 0 if the unaffected sibling has the rare variant. We obtain an aggregate score by summing over all independent siblings:
Under the null hypothesis, the aggregate score should be distributed according to a binomial distribution. So, if there are a total of n siblings , we can calculate P sibling , the one-tailed significance as where the function 'binomial' represents the binomial distribution for x successful draws out of n siblings , each with a probability of 0.5.
To perform aggregate meta-analysis, we defined a score s aggregate , which is the total of s variant,case across all strata and siblings. We can calculate the probability of obtaining the score s or a more significant score to determine the exact one-tailed P value: 
Association testing. We tested nonsynonymous, splice acceptor site and splice donor site, start-loss, stop-gain and stop-loss variants for associations that were rare variants (f ≤ 0.01 in either cases or controls). We only included rare variants with a minor allele count of ≥5 in our data set. To conduct stratified testing for other nearby common SNPs, we further subdivided strata on the basis of common variant genotypes. Burden testing. To test for burden, we identified those variants that altered coding sequences (missense, altered splice acceptor sites or splice donor sites, a start lost or a stop gained or lost) and were present with low allele frequencies (f < 0.01 in all subjects). We tested in two ways: (i) assessing whether rare variants within a gene had increased frequencies in cases compared to controls and then (ii) assessing whether rare variants had increased frequencies in controls compared to cases. We used the exact statistical framework described above to test for aggregate effects.
Defining CFH haplotypes. We used sequence-based genotype data from individuals that had 0% missing genotypes for CFH markers used in our previous study to define haplotypes 5 , and constructed haplotypes with Beagle 56 . We selected haplotypes with frequencies >0.5%, and calculated case and control frequencies. For each haplotype we calculated odds ratios and 95% confidence intervals relative to the most frequent haplotype.
Adjusting for stratification. We reassessed association statistics for C3 K155Q and rare CFI coding variants after adjusting for stratification in a subset of sequenced samples with exome-chip data (1,558 cases and 683 controls). We applied EIGENSTRAT to calculate principal components to capture ancestry information and exclude outliers in sequenced samples 55 . For sequenced samples we plotted carriers of C3 K155Q and also of CFI rare variants along the first two components to look for gross evidence of stratification. We also re-assessed two-tailed association statistics by adjusting for the top 5 principal components in a logistic regression framework. Since logistic regression can be unstable for rare events, in the case of C3 K155Q we reported two-tailed significance by calculating beta with the actual data, and comparing it to a null beta distribution defined by permuting case-control labels 1,000,000 times.
Adjusting for age and gender. For samples used in the sequencing study, we had information on sex for all samples and information on age for almost all (2,457) samples. Here age was defined for controls as the age of npg ophthalmological evaluation and for cases as the age at which they had their first ophthalmological evaluation on record confirming advanced disease. We calculated two-tailed association statistics by adjusting for both age and sex with a logistic regression framework. Similar to the approach we took for adjusting for population stratification, for the C3 variant encoding p.Lys155Gln we reported two-tailed significance by calculating β with the actual data and comparing it to a null β distribution defined by permuting case-control labels 1 million times. Protein expression. We applied site-directed mutagenesis using QuikChange (Agilent Technologies) to modify wild-type C3 cDNA with the allele encoding Lys155 to instead contain the mutation encoding Gln155. We produced C3 proteins with Lys155 or Gln155 by transient transfection of 293T cells with TransIt 293 (Mirus) and collected and concentrated cell supernatants 3 d after transfection. Cells were obtained from ATCC (American Type Culture Collection) where they were tested for mycoplasma. We treated transfection supernatants with methylamine to convert native C3 into a C3b-like form, C3-methylamine. We quantified C3 by ELISA, surface plasmon resonance and protein blotting as previously described 30 .
Ligand binding assays. To assess binding of the C3 proteins with Lys155 or Gln155 to regulators, we used ELISAs as previously described 30 . Briefly, we coated either soluble membrane cofactor protein (sMCP), CFH or soluble complement receptor 1 (sCR1) (each at 2 µg/ml) onto wells in PBS overnight at 4 °C followed by an incubation with a blocking buffer at 37 °C for 60 min. We prepared dilutions of C3 protein with Lys155 or Gln155 in a low-salt (25 mM) ELISA buffer. After incubation at 37 °C for 1 h, wells were washed, and we then applied affinity-purified chicken antibody to human C3 (1:10,000 dilution; Biodesign International) for 1 h at 37 °C. After washing, we applied HRP-linked donkey antibody to chicken IgY (1:10,000 dilution) for 1 h at 37 °C. After washing, we added TMB substrate and quantified absorbance at 630 nm.
Surface plasmon resonance (SPR) analysis. We performed SPR analysis using the BIAcore 2000 (GE Lifesciences). Using standard amine-coupling technology (GE Lifesciences), sMCP, CFH or monoclonal antibody to C3d was coupled to individual flow paths. We activated one flow path in each chip without protein as a reference. The running buffer was composed of 10 mM HEPES, pH 7.4, 25 mM NaCl and 0.005% Tween-20. We injected C3 protein encoding Lys155 or Gln155 for 90 s at 30 µl/min and monitored dissociation for 300 s. We regenerated the chip by injecting 0.5 M NaCl. We analyzed each protein at four concentrations with a minimum of two injections per concentration. These experiments were performed three times using independently produced and quantified C3 preparations. We analyzed data using BIAeval software from BIAcore.
Cofactor assays. We assessed cleavage of the C3 proteins with Lys155 or Gln155 by CFI using previously described cofactor assays 30 . C3 preparations were incubated for 0 to 30 min at 37 °C with CFI (5 ng in MCP and 20 ng in CFH assays) and a cofactor protein MCP (50 ng; recombinant) or CFH (200 ng) in 15 µl of buffer (10 mM Tris, pH 7.4, 150 mM NaCl). To stop the reaction, we added 7 µl of 3× reducing Laemmli sample buffer. Samples were boiled at 95 °C for 5 min, electrophoresed on 10% Tris-glycine polyacrylamide gels, transferred to nitrocellulose and blocked overnight with 5% nonfat dry milk in PBS. We probed the blots with a 1:5,000 dilution of goat antibody to human C3 followed by HRP-conjugated rabbit antibody to goat IgG. We developed the blots with SuperSignal substrate.
